This company listing is no longer active
GNRS Stock Overview
Greenrose Holding Company Inc., through its subsidiaries, engages in the production and sale of cannabis products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
The Greenrose Holding Company Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.28 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.95% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Shareholder Returns
| GNRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | -100.0% | 14.2% | 32.3% |
Return vs Industry: GNRS underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: GNRS underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| GNRS volatility | |
|---|---|
| GNRS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNRS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GNRS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Nicole Conboy | www.greenroseholdings.com |
Greenrose Holding Company Inc., through its subsidiaries, engages in the production and sale of cannabis products. It engages in cultivating, processing, and packaging medical cannabis and derivative products. The company was founded in 2014 and is headquartered in Amityville, New York.
The Greenrose Holding Company Inc. Fundamentals Summary
| GNRS fundamental statistics | |
|---|---|
| Market cap | US$1.77k |
| Earnings (TTM) | US$13.45m |
| Revenue (TTM) | US$28.40m |
0.0x
P/E Ratio0.0x
P/S RatioIs GNRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNRS income statement (TTM) | |
|---|---|
| Revenue | US$28.40m |
| Cost of Revenue | US$9.83m |
| Gross Profit | US$18.57m |
| Other Expenses | US$5.12m |
| Earnings | US$13.45m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GNRS perform over the long term?
See historical performance and comparison